{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:16:10Z","timestamp":1789895770085,"version":"4.0.1"},"reference-count":71,"publisher":"Portland Press Ltd.","issue":"1","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,8]]},"abstract":"<jats:p>Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD), resembling the sporadic disorder. Intensive effort has been directed toward LRRK2 mouse modeling and investigation, aimed at reproducing the human disease to inform mechanistic studies of pathogenesis and design of neuroprotective therapies. The physiological function of LRRK2 is still under exploration, but a clear role in striatal neurophysiology and animal behavior has emerged. Alterations in LRRK2 impair dopamine (DA) transmission, regulation and signaling, in addition to corticostriatal synaptic plasticity. Consistently, several subtle abnormalities in motor and nonmotor abilities have been demonstrated in LRRK2 genetic mouse models, generally paralleling preclinical symptoms of early DA dysfunction. However, the variability in model design and phenotypes observed requires a critical approach in interpreting the results, adapting the model used to the specific research question. Etiologically appropriate knockin mice might represent the ultimate animal model in which to study early disease mechanisms and therapies as well as to investigate drug effectiveness and off-target consequences.<\/jats:p>","DOI":"10.1042\/bst20160238","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T18:05:22Z","timestamp":1487181922000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis"],"prefix":"10.1042","volume":"45","author":[{"given":"Mattia","family":"Volta","sequence":"first","affiliation":[{"name":"Center for Biomedicine, EURAC Research, Via Galvani 31, Bolzano 39100, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Melrose","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"2021111720292418700_BST-2016-0238C1","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson's disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2021111720292418700_BST-2016-0238C2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/gm566","article-title":"Genetics and genomics of Parkinson's disease","volume":"6","author":"Lin","year":"2014","journal-title":"Genome Med."},{"key":"2021111720292418700_BST-2016-0238C3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"2021111720292418700_BST-2016-0238C4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/mds.24051","article-title":"Toward a redefinition of Parkinson's disease","volume":"27","author":"Stern","year":"2012","journal-title":"Mov. Disord."},{"key":"2021111720292418700_BST-2016-0238C5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"issue":"2 Suppl","key":"2021111720292418700_BST-2016-0238C6","first-page":"S59","article-title":"Parkinson's disease \u2014 part 3: neuropsychiatric symptoms","volume":"14","author":"Weintraub","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"2021111720292418700_BST-2016-0238C7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"2021111720292418700_BST-2016-0238C8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ana.20731","article-title":"Lrrk2 and Lewy body disease","volume":"59","author":"Ross","year":"2006","journal-title":"Ann. Neurol."},{"key":"2021111720292418700_BST-2016-0238C9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.parkreldis.2012.03.024","article-title":"LRRK2 I2020T mutation is associated with tau pathology","volume":"18","author":"Ujiie","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"2021111720292418700_BST-2016-0238C10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc055540","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs","volume":"354","author":"Lesage","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021111720292418700_BST-2016-0238C11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMc055509","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews","volume":"354","author":"Ozelius","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2021111720292418700_BST-2016-0238C12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.neurobiolaging.2013.11.015","article-title":"A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism","volume":"35","author":"Trinh","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"2021111720292418700_BST-2016-0238C13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.26075","article-title":"Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic","volume":"30","author":"West","year":"2015","journal-title":"Mov. Disord."},{"key":"2021111720292418700_BST-2016-0238C14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/mds.23696","article-title":"A tale on animal models of Parkinson's disease","volume":"26","author":"Bezard","year":"2011","journal-title":"Mov. Disord."},{"key":"2021111720292418700_BST-2016-0238C15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev.neuro.051508.135422","article-title":"Physiology and pharmacology of striatal neurons","volume":"32","author":"Kreitzer","year":"2009","journal-title":"Annu. Rev. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and indirect pathways of basal ganglia: a critical reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C17","doi-asserted-by":"publisher","first-page":"14845","DOI":"10.1073\/pnas.1009874107","article-title":"Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors","volume":"107","author":"Bateup","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111720292418700_BST-2016-0238C18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","article-title":"Dopamine-mediated regulation of corticostriatal synaptic plasticity","volume":"30","author":"Calabresi","year":"2007","journal-title":"Trends Neurosci."},{"key":"2021111720292418700_BST-2016-0238C20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson's disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"2021111720292418700_BST-2016-0238C21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-150769","article-title":"Retrograde axonal degeneration in Parkinson disease","volume":"6","author":"Tagliaferro","year":"2016","journal-title":"J. Parkinson's Dis."},{"key":"2021111720292418700_BST-2016-0238C22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neuroscience.2006.01.017","article-title":"Anatomical localization of leucine-rich repeat kinase 2 in mouse brain","volume":"139","author":"Melrose","year":"2006","journal-title":"Neuroscience"},{"key":"2021111720292418700_BST-2016-0238C23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.neuroscience.2007.05.027","article-title":"A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease","volume":"147","author":"Melrose","year":"2007","journal-title":"Neuroscience"},{"key":"2021111720292418700_BST-2016-0238C24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.expneurol.2010.05.004","article-title":"Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys","volume":"224","author":"Lee","year":"2010","journal-title":"Exp. Neurol."},{"key":"2021111720292418700_BST-2016-0238C25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1042\/BST20120124","article-title":"Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2","volume":"40","author":"Belluzzi","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"2021111720292418700_BST-2016-0238C26","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0520s31","article-title":"An overview on the generation of BAC transgenic mice for neuroscience research","author":"Yang","year":"2005","journal-title":"Curr. Protoc. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C27","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1523\/JNEUROSCI.5604-09.2010","article-title":"Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S","volume":"30","author":"Li","year":"2010","journal-title":"J. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nn.2349","article-title":"Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease","volume":"12","author":"Li","year":"2009","journal-title":"Nat. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.nbd.2010.07.010","article-title":"Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice","volume":"40","author":"Melrose","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"2021111720292418700_BST-2016-0238C30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/hmg\/ddu543","article-title":"LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory","volume":"24","author":"Beccano-Kelly","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"2021111720292418700_BST-2016-0238C31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1750-1326-7-15","article-title":"The I2020T leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities","volume":"7","author":"Maekawa","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"2021111720292418700_BST-2016-0238C32","doi-asserted-by":"publisher","first-page":"e18568","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS ONE"},{"key":"2021111720292418700_BST-2016-0238C33","doi-asserted-by":"publisher","first-page":"e94826","DOI":"10.1371\/journal.pone.0094826","article-title":"Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice","volume":"9","author":"Sanchez","year":"2014","journal-title":"PLoS ONE"},{"issue":"Pt 1","key":"2021111720292418700_BST-2016-0238C34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.expneurol.2015.09.001","article-title":"(R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model","volume":"275","author":"Weng","year":"2016","journal-title":"Exp. Neurol."},{"key":"2021111720292418700_BST-2016-0238C35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.nbd.2014.08.027","article-title":"Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration","volume":"71","author":"Tsika","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"2021111720292418700_BST-2016-0238C36","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1093\/hmg\/ddv249","article-title":"Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression","volume":"24","author":"Liu","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"2021111720292418700_BST-2016-0238C37","doi-asserted-by":"publisher","first-page":"e0118947","DOI":"10.1371\/journal.pone.0118947","article-title":"No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts","volume":"10","author":"Garcia-Miralles","year":"2015","journal-title":"PLoS ONE"},{"key":"2021111720292418700_BST-2016-0238C38","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.parkreldis.2015.07.025","article-title":"Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release","volume":"21","author":"Volta","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"2021111720292418700_BST-2016-0238C39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1750-1326-7-25","article-title":"LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors","volume":"7","author":"Hinkle","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"2021111720292418700_BST-2016-0238C40","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","article-title":"LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice","volume":"20","author":"Herzig","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"2021111720292418700_BST-2016-0238C41","doi-asserted-by":"publisher","first-page":"9879","DOI":"10.1073\/pnas.1004676107","article-title":"Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of \u03b1-synuclein, and apoptotic cell death in aged mice","volume":"107","author":"Tong","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111720292418700_BST-2016-0238C42","doi-asserted-by":"publisher","first-page":"14622","DOI":"10.1073\/pnas.0906334106","article-title":"R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice","volume":"106","author":"Tong","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111720292418700_BST-2016-0238C43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nbd.2015.02.031","article-title":"Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice","volume":"78","author":"Yue","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"2021111720292418700_BST-2016-0238C44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fncel.2014.00301","article-title":"Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice","volume":"8","author":"Beccano-Kelly","year":"2014","journal-title":"Front Cell Neurosci."},{"key":"2021111720292418700_BST-2016-0238C45","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.1523\/JNEUROSCI.3314-15.2016","article-title":"Altered development of synapse structure and function in striatum caused by Parkinson's disease-linked LRRK2-G2019S mutation","volume":"36","author":"Matikainen-Ankney","year":"2016","journal-title":"J. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C46","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nbd.2014.04.021","article-title":"(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse","volume":"68","author":"Chou","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"2021111720292418700_BST-2016-0238C47","doi-asserted-by":"publisher","first-page":"11190","DOI":"10.1523\/JNEUROSCI.0040-15.2015","article-title":"The Parkinson's disease-associated mutation LRRK2-G2019S impairs synaptic plasticity in mouse hippocampus","volume":"35","author":"Sweet","year":"2015","journal-title":"J. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C48","doi-asserted-by":"publisher","first-page":"e70249","DOI":"10.1371\/journal.pone.0070249","article-title":"Non-motor and motor features in LRRK2 transgenic mice","volume":"8","author":"Bichler","year":"2013","journal-title":"PLoS ONE"},{"key":"2021111720292418700_BST-2016-0238C49","doi-asserted-by":"publisher","first-page":"e36581","DOI":"10.1371\/journal.pone.0036581","article-title":"High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain","volume":"7","author":"Herzig","year":"2012","journal-title":"PLoS ONE"},{"key":"2021111720292418700_BST-2016-0238C50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","article-title":"Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant \u03b1-synuclein","volume":"64","author":"Lin","year":"2009","journal-title":"Neuron"},{"key":"2021111720292418700_BST-2016-0238C51","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1038\/cdd.2012.42","article-title":"(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD","volume":"19","author":"Chen","year":"2012","journal-title":"Cell Death Differ."},{"key":"2021111720292418700_BST-2016-0238C52","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nn.3636","article-title":"LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity","volume":"17","author":"Parisiadou","year":"2014","journal-title":"Nat. Neurosci."},{"key":"2021111720292418700_BST-2016-0238C53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ncomms1161","article-title":"Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor","volume":"2","author":"Hanafusa","year":"2011","journal-title":"Nat. Commun."},{"key":"2021111720292418700_BST-2016-0238C54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.mad.2010.01.009","article-title":"Heterodimerization of Lrrk1-Lrrk2: implications for LRRK2-associated Parkinson disease","volume":"131","author":"Dachsel","year":"2010","journal-title":"Mech. Ageing Dev."},{"key":"2021111720292418700_BST-2016-0238C55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mds.21180","article-title":"Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families","volume":"22","author":"Ishihara","year":"2007","journal-title":"Mov. Disord."},{"key":"2021111720292418700_BST-2016-0238C56","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/archneur.63.9.1250","article-title":"Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations","volume":"63","author":"Ishihara","year":"2006","journal-title":"Arch. Neurol."},{"key":"2021111720292418700_BST-2016-0238C57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13311-010-0007-z","article-title":"Neuroimaging in Parkinson's disease","volume":"8","author":"Stoessl","year":"2011","journal-title":"Neurotherapeutics"},{"key":"2021111720292418700_BST-2016-0238C58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.nbd.2014.07.013","article-title":"Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging","volume":"71","author":"Longo","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"2021111720292418700_BST-2016-0238C59","doi-asserted-by":"publisher","first-page":"e12813","DOI":"10.7554\/eLife.12813","article-title":"Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases","volume":"5","author":"Steger","year":"2016","journal-title":"eLife"},{"key":"2021111720292418700_BST-2016-0238C60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1152\/physrev.00059.2009","article-title":"Role of Rab GTPases in membrane traffic and cell physiology","volume":"91","author":"Hutagalung","year":"2011","journal-title":"Physiol. Rev."},{"key":"2021111720292418700_BST-2016-0238C61","doi-asserted-by":"publisher","first-page":"a005637","DOI":"10.1101\/cshperspect.a005637","article-title":"Synaptic vesicle exocytosis","volume":"3","author":"Sudhof","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2021111720292418700_BST-2016-0238C62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1073\/pnas.0710685105","article-title":"The Parkinson's disease protein \u03b1-synuclein disrupts cellular Rab homeostasis","volume":"105","author":"Gitler","year":"2008","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111720292418700_BST-2016-0238C63","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/mds.23781","article-title":"Genomewide linkage study of modifiers of LRRK2-related Parkinson's disease","volume":"26","author":"Latourelle","year":"2011","journal-title":"Mov. Disord."},{"key":"2021111720292418700_BST-2016-0238C64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JPD-140344","article-title":"Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging","volume":"4","author":"Walker","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"2021111720292418700_BST-2016-0238C65","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/hmg\/ddv628","article-title":"LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function","volume":"25","author":"Sloan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"2021111720292418700_BST-2016-0238C66","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7150\/ijbs.7.753","article-title":"Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake","volume":"7","author":"Zhou","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"2021111720292418700_BST-2016-0238C67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/BJ20100483","article-title":"14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization","volume":"430","author":"Nichols","year":"2010","journal-title":"Biochem. J."},{"key":"2021111720292418700_BST-2016-0238C68","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.parkreldis.2010.08.018","article-title":"A comparative study of Lrrk2 function in primary neuronal cultures","volume":"16","author":"D\u00e4chsel","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"2021111720292418700_BST-2016-0238C69","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw068","article-title":"Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt\/Nrf pathway and inhibiting GSK3beta activity","author":"Lin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"2021111720292418700_BST-2016-0238C70","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/acn3.45","article-title":"LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity","volume":"1","author":"Liu","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2021111720292418700_BST-2016-0238C71","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1042\/BCJ20160557","article-title":"Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors","volume":"473","author":"Ito","year":"2016","journal-title":"Biochem. J."}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/45\/1\/113\/432585\/bst-2016-0238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/45\/1\/113\/432585\/bst-2016-0238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:31:24Z","timestamp":1637195484000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/45\/1\/113\/66304\/LRRK2-mouse-models-dissecting-the-behavior"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,8]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,15]]},"published-print":{"date-parts":[[2017,2,8]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20160238","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,8]]}}}